Sugi Predict

Sugi Predict / Compounds / SCHEMBL791306

SCHEMBL791306

SCHEMBL791306

Cc1ccc(S(=O)(=O)OCCNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 10/20 0.56
▸ CA1 P00915 8/20 0.56
▸ CA12 O43570 5/20 0.56
▸ CA9 Q16790 5/20 0.56
▸ IDO1 P14902 1/20 0.43
▸ CCNC P24863 1/20 0.43
▸ CDK8 P49336 1/20 0.43
▸ EGFR P00533 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ STAT3 P40763 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ MALT1 Q9UDY8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21071071 0.92 CA1 (0.52) CA2CA1CA12CA9IDO1
SCHEMBL26102679 0.92 CA1 (0.52) CA2CA1CA12CA9IDO1
SCHEMBL8073830 0.92 CA1 (0.52) CA2CA1CA12CA9IDO1
SCHEMBL3289002 0.92 CA1 (0.52) CA2CA1CA12CA9IDO1
SCHEMBL14745101 0.92 CA1 (0.52) CA2CA1CA12CA9IDO1
SCHEMBL31235782 0.92 CA1 (0.52) CA2CA1CA12CA9IDO1
SCHEMBL6757589 0.92 CA1 (0.52) CA2CA1CA12CA9IDO1
SCHEMBL21531171 0.92 CA1 (0.52) CA2CA1CA12CA9IDO1
SCHEMBL487585 0.92 CA1 (0.59) CA2CA1CA12CA9CCNC
SCHEMBL2822013 0.91 CA1 (0.60) CA2CA1CA12CA9CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2026-03-12 — — US disclosed
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2025-07-17 — — US disclosed
EP-4580405-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL Oerth Bio LLC (US) 2025-07-09 — — EP disclosed
CN-119954715-A Preparation method of doxylamine succinate 金陵药业股份有限公司 2025-05-09 — — CN disclosed
WO-2024050016-A9 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2025-04-03 — — WO disclosed
WO-2025049555-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL OERTH BIO LLC (US) 2025-03-06 — — WO disclosed
US-12171831-B2 Compounds and methods for the targeted degradation of bromodomain- containing proteins ARVINAS OPERATIONS, INC. (US) 2024-12-24 — — US disclosed
US-20240408218-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS Københavns Universitet (DK) 2024-12-12 — — US disclosed
WO-2024238598-A2 STAT DEGRADERS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2024-11-21 — — WO disclosed
EP-4408475-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS Københavns Universitet (DK) 2024-08-07 — — EP disclosed
CN-1101816-C Substituted purine derivatives, their preparation, their use and compositions containing them HOECHST AG (DE) 2003-02-19 — — CN disclosed
WO-2002083687-A1 3,7-DIAZYBICYCLO [3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS ASTRAZENECA AB (SE) 2002-10-24 — — WO disclosed
WO-2002083690-A1 NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES ASTRAZENECA AB (SE) 2002-10-24 — — WO disclosed
WO-2002083689-A1 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS ASTRAZENECA AB (SE) 2002-10-24 — — WO disclosed
WO-2002083688-A1 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS ASTRAZENECA AB (SE) 2002-10-24 — — WO disclosed
US-6271251-B1 CARDIOVASCULAR DISORDERS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2001-08-07 — — US disclosed
US-5977100-A Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1999-11-02 — — US disclosed
US-5834454-A TREATMENT OF ANGINA, ISCHEMIA, ARRHYTHMIA SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1998-11-10 — — US disclosed
CN-1193623-A Substituted purine derivatives, their preparation, their use and compositions containing them HOECHST AG (DE) 1998-09-23 — — CN disclosed
EP-0787728-A1 Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1997-08-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240408218-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS GLP1R, PRKAG1, GCGR CA2 2997/4885CA1 3302/4885CA12 3311/4885
US-12171831-B2 Compounds and methods for the targeted degradation of bromodomain- containing proteins BRPF3, STUB1, BRDT CA2 3350/4885CA1 2626/4885CA12 3495/4885
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT CA2 3350/4885CA1 2626/4885CA12 3495/4885
US-20260068886-A1 COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL CRBN, STUB1, CUL1 CA2 3448/4885CA1 2819/4885CA12 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.